Many everyday symptoms are inconsequential. You have a poor night’s sleep to thank for your bloodshot eyes, or a new lotion ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Once again, a new strain of COVID has hit the country, and that includes Rhode Island. According to the Centers for Disease ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9.

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV ...

In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01 E ...

Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna. June 12, 2025.

The researchers noted demographic and illness characteristics were similar between patients with RSV type A and those with RSV type B. The estimated overall seasonal incidence of outpatient ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...